Moxifloxacin: A review of its safety profile based on worldwide clinical trials

Today's Therapeutic Trends

Volumn 18, Issue 3, 2000, Pages 205-223

  Church, D ^a   Haverstock, D ^a   Andriole, V T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; LIVER DYSFUNCTION; MORAXELLA CATARRHALIS; NAUSEA; PNEUMONIA; POSTMARKETING SURVEILLANCE; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; VERTIGO;

EID: 0033811934     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
2. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season
3. Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens
4. Prevalence of antimicrobial resistance among respiratory, tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
5. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
6. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
7. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone
8. In vitro activity of BAY 12-8039, a new fluoroquinolone
9. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin
10. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
11. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis
12. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis
13. Short course treatment of acute sinusitis with moxifloxacin versus cefuroxime axetil
14. Moxifloxacin (MXF) in acute sinusitis (AS) - A bacteriological and clinical meta-analysis. Abstract P0204
15. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis
16. Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
17. Moxifloxacin (MXF) in acute exacerbations of chronic bronchitis (AECB) - A bacteriological and clinical meta-analysis. Abstract P0203
18. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia
19. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia
20. Moxifloxacin versus amoxicillin in the treatment of community acquired, suspected pneumococcal pneumonia: A multinational, double-blind randomised study. Abstract P0207
21. Moxifloxacin (MSF) in community acquired pneumonia (CAP) - A bacteriological and clinical meta-analysis. Abstract P0205
22. Tolerability of quinolone antibiotics: Past, present, and future
23. The withdrawal of temafloxacin
24. Overview of fluoroquinolone safety
25. Clinical features and management of adverse effects of quinolone antibacterials
26. Adverse reactions to fluoroquinolones in adults and children
27. Safety of the fluoroquinolones
28. Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance
29. Safety overview: Toxicity, adverse effects and drug interactions
30. Fluoroquinolone antibiotics: Adverse effects and safety profiles
31. Structure-activity and structure side effect relationships for the quinolone antibacterials
32. Quinolones: Structure activity relationships and future predictions
33. Fluoroquinolone phototoxicity: A comparison of moxifloxacin and lomefloxacin in normal volunteers
34. Phototoxicity in quinolones: Comparison of ciprofloxacin and grepafloxacin
35. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation
36. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin
37. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QT(c) interval)
38. Cardiac actions of erythromycin. Influence of female sex
39. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concomitant QT(c)-prolonging drugs
40. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
41. FDC Report: FDA/PhRMA task force to assess QT risk by pre-clinical markers
42. QTc prolongation associated with levofloxacin
43. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin
44. Comparative tolerability of the newer fluoroquinolone antibacterials
45. The QT interval and drug-associated Torsade de Pointes